Global X Genomics & Biotechnology ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 6M SHOWN
Flows are quiet — the past month netted out near zero, while the price has returned +46.2% so far this year. At 0.50% a year it is not the cheapest way in — IBRN runs the same ground at 0.47%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS TODAY’S MOVE · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | MRNAMODERNA | 7.10% | $145.13 | +8.9% | ||
| 2 | TWSTTWIST BIOSCIENCE | 6.20% | $145.59 | +6.8% | ||
| 3 | TXG10X GENOMICS | 5.58% | $65.12 | +2.0% | ||
| 4 | GHGUARDANT HEALTH | 5.55% | $170.69 | +1.7% | ||
| 5 | ILMNILLUMINA | 4.84% | $219.40 | +2.9% | ||
| 6 | NTRANATERA | 4.63% | $332.03 | +2.2% | ||
| 7 | VRTXVERTEX PHARMACEUTICALS | 3.65% | $548.05 | +1.4% | ||
| 8 | TECHBIO-TECHNE | 3.65% | $72.32 | +0.1% | ||
| 9 | BMRNBIOMARIN PHARMACEUTICAL | 3.70% | $66.70 | -1.4% | ||
| 10 | ARWRARROWHEAD PHARMACEUTICALS | 3.50% | $87.11 | -0.4% | ||
| 11 | PRAXPRAXIS PRECISION MEDICINES | 3.20% | $375.94 | +3.1% | ||
| 12 | QGENQIAGEN NV | 3.33% | $44.07 | -1.8% | ||
| 13 | BNTXBIONTECH SE | 3.02% | $116.57 | +5.1% | ||
| 14 | CRSPCRISPR THERAPEUTICS AG | 3.05% | $59.50 | +2.4% | ||
| 15 | VCYTVERACYTE | 2.51% | $42.31 | +1.2% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 41| 1 week | +13.0% |
| 1 month | +23.7% |
| 3 months | +43.5% |
| 6 months | +41.3% |
| YTD | +46.2% |
| 1 year | +614.4% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | — |
| 3 months | — |
| YTD | — |
| 1 year | — |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 7.1% of the book; the top ten carry 49%. Spread across 50+ names, it behaves like roughly 28 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $178M | $164M |
| LLY ELI LILLY | $65M | $59M |
| BMY BRISTOL MYERS SQUIBB | $3M | $3M |
| VRTX VERTEX PHARMACEUTICALS | $1M | $3M |
| BNTX BIONTECH SE | $2M | $2M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat GNOM on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.03% | $97.9B | +$245M | -47bp on fee · 1157× the assets · +$245M in over the month | Head-to-head |
| IUSG iShares Core S&P U.S. Growth ETF | 0.04% | $33.8B | +$668M | -46bp on fee · 399× the assets · +$668M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.7B | +$104M | -46bp on fee · 386× the assets · +$104M in over the month | Head-to-head |
| IUSV iShares Core S&P U.S. Value ETF | 0.04% | $28.1B | +$103M | -46bp on fee · 332× the assets · +$103M in over the month | Head-to-head |
| IVV iShares Core S&P 500 ETF | 0.03% | $900.9B | −$14.2B | -47bp on fee · 10641× the assets | Head-to-head |